Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008 in New York City. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company; highlight details on the recent market performance of ANTARA®(fenofibrate) capsules and FACTIVE® (gemifloxacin mesylate) tablets; and discuss the Company's recently announced results for the third quarter of 2008, in which Oscient recorded $21.8 million in revenues.
The presentation will begin at 3:40 pm ET on Tuesday and will be webcast through the Company’s website at www.oscient.com.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States: ANTARA® (fenofibrate) capsules, a cardiovascular product and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a national sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists.
For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com. For a complete description of the risks associated with our business please refer to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2008 and in other filings that we may make with the Securities and Exchange Commission from time to time.
Contacts:
Christopher Taylor, 781-398-2466
or
Sandra
Schmidt Coombs, 781-398-2310
